Harnessing siRNA Technologies to Achieve Precise Complement Modulation Across an Increased Range of Indications

• Exploring the advantages of siRNA-based approaches for reducing complement protein production and enabling durable pathway inhibition
• Assessing target selection, dosing strategies and safety considerations to optimize efficacy across complement-mediated diseases
• Demonstrating how next-generation RNA technologies are expanding treatment options and addressing unmet patient needs

Speakers:

Karoline Meagher

Associate Director, Precision Medicine

Regeneron